SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/20.09.24

SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/20.09.24 Share Price

DE000SY0AT87

Market Closed - Boerse Frankfurt Warrants 19:16:15 03/07/2024 BST
1.25 ^EUR	+3.31%

Current month	-12.32%
1 month	-43.19%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	07-02	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	07-02	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	CI

More news

Quotes 5-day view

Date	Price	Change
03/07/24	1.25	+3.31%
02/07/24	1.21	-7.63%
01/07/24	1.31	-5.07%
28/06/24	1.38	+11.29%
27/06/24	1.24	-3.13%

Real-time Boerse Frankfurt Warrants

Last update July 03, 2024 at 07:16 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Société Générale
WKN	SY0AT8
ISIN	DE000SY0AT87
Date issued	13/05/2024
Strike	450 $
Maturity	20/09/2024 (79 Days)
Parity	10 : 1
Emission price	3.95 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	3.63 €
Lowest since issue	1.13 €
Delta	-0.32x
Omega	10.52
Premium	7.33x
Gearing	33.16x
Moneyness	0.9569
Difference Strike	-20.28 $
Difference Strike %	-4.51%
Spread	0.13 €
Spread %	9.42%
Theoretical value	1.315
Implied Volatility	29.29 %
Total Loss Probability	63.29 %
Intrinsic value	0.000000
Present value	1.315
Break even	435.82 €
Theta	-0.08x
Vega	0.07x
Rho	-0.03x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company